Global Orthodontists Gather in Europe to Explore Smartee's Breakthrough in Mandibular Repositioning
ROME, July 10, 2025 /PRNewswire/ — Smartee hosted two European academic symposia on GS Mandibular Repositioning Technology, drawing orthodontists from over 10 countries to Brussels and Rome. These events marked a pivotal milestone in Smartee's mission to advance orthodontic excellence through cross-continental clinical exchange.
Held in the heart of Europe, the Brussels symposium presented an in-depth program that covered the core principles and clinical applications of Smartee GS Mandibular Repositioning Technology. Attendees engaged in immersive GS theory workshops, hands-on practice, and complex case reviews, equipping clinicians with practical strategies for treating severe malocclusions.
During the symposium, Prof. Gang Shen offered an in-depth clinical framework for managing adult cases of 'three-depth malocclusion'—a pattern characterized by mandibular retrusion, facial convexity, increased overjet, deep overbite, a pronounced Curve of Spee, and Class II molar relationship.
Recognizing that surgical repositioning or maxillary extractions are often undesired by adult patients, Prof. Shen proposed a non-invasive, staged treatment approach. In the initial phase, aligners equipped with vertical bite blocks are combined with the S8-SGTB appliance to guide anterior mandibular repositioning. Then perform simultaneous incisor intrusion and molar extrusion. This protocal not only advances the mandible but also facilitates remodeling in the condylar region through adaptive bone deposition posterior to the joint.
This strategy enables clinicians to improve facial profile, optimize dental function, and minimize invasive interventions, redefining how clear aligners can serve complex skeletal malocclusion cases.
The Rome symposium continued this momentum, reinforcing Smartee's commitment to elevating global orthodontic standards. Both events facilitated robust dialogue between European clinicians and Smartee's scientific leadership, highlighting the appliance's clinical efficacy in treating Class II malocclusions and jaw discrepancies.
Orthodontists from over ten countries, including France, Germany, Switzerland, the Netherlands, and Lebanon, attended the events, underscoring the growing international interest on GS Mandibular Repositioning Technology.
Dr. Camilla Molinari, orthodontic specialist, shared her thoughts, 'These sessions revealed groundbreaking applications of GS Mandibular Repositioning Technology for complex malocclusions. Prof. Gang Shen's insights and the compelling case data shared will meaningfully enhance our approach to Class II cases. I believe this will be transformative for clinical practice.'
Dr. Versace Piero added, 'Smartee's GS course delivered exceptional clarity and innovation. The methodology provides tangible clinical value, and I anticipate integrating it into my practice. This technology represents the future of precision-driven orthodontics.'
These symposia represent Smartee's transition from aligner exporter to global technology innovator, with GS Mandibular Repositioning emerging as a pioneering framework for complex cases. By exporting validated scientific protocols alongside its aligner systems, Smartee enables clinicians worldwide to achieve consistent, physiologically sound outcomes.
Photo – https://mma.prnewswire.com/media/2727593/Smartee_GS_Mandibular_Repositioning_Technology_Seminar_Speaker_Prof_Gang_Shen.jpg
View original content:https://www.prnewswire.com/news-releases/global-orthodontists-gather-in-europe-to-explore-smartees-breakthrough-in-mandibular-repositioning-302501872.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
2026 Medicare Physician Fee Schedule Rates Set for Scalp Cooling CPT Codes
SAN DIEGO, July 15, 2025 /PRNewswire/ — Cooler Heads, a health tech company dedicated to making scalp cooling more accessible and affordable for people undergoing chemotherapy, celebrates a major milestone in the effort to expand access to their hair-preserving treatment. The Centers for Medicare & Medicaid Services (CMS) has released its 2026 Medicare Physician Fee Schedule (MPFS) Proposed Rule, which includes three new Category I CPT® codes for mechanical scalp cooling, each assigned a proposed payment rate. This is the first time scalp cooling has been included in the Medicare Physician Fee Schedule, marking a critical step forward in establishing consistent reimbursement. 'This decision is important for patients suffering from hair loss, a devastating and visible side effect of chemotherapy,' said Kate Dilligan, Founder and CEO of Cooler Heads. 'These new codes and proposed rates are a positive step towards helping all patients undergoing treatment for solid tumor cancers preserve their identity during treatment.' CMS has proposed payment rates for three new CPT® codes related to mechanical scalp cooling. The first code, covering the initial fitting of the scalp cooling cap and patient education, would be reimbursed at $1,701. The second code, for the pre-infusion cooling period, is proposed at $10 per treatment. The third code, covering the post-infusion cooling period in 30-minute increments, would be reimbursed at $6 per unit. The new codes do not apply to manual cold caps, highlighting the importance of FDA-cleared mechanical scalp cooling systems like Amma™. This decision also sets a precedent for private insurers to develop their own coverage policies, increasing the likelihood of broader access to patients. After the public comment period concludes on September 12, 2025, and any subsequent updates are made, CMS is expected to release the Final Rule in November 2025. The revised Medicare Physician Fee Schedule (MPFS) rates and updated CPT codes will take effect on January 1, 2026. This timeline presents an exciting opportunity for Cooler Heads to collaborate with health systems. Contact:press@ About Cooler Heads: Cooler Heads, based in San Diego, provides evidence-based products, content, and services that cancer patients need to manage the challenging side effects of treatment. Founded by a cancer survivor, Cooler Heads is driven by the mission to reduce the physical and emotional toll of cancer treatment, offering tools like Amma to improve the quality of life for patients.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Global Influenza Market Surges Amid Diagnostic Innovation
'Rise in Influenza Cases Drives Demand for Rapid Diagnostics and Molecular Testing Solutions, Fueling Innovation and Growth Across the Global Influenza Market' BOSTON, July 15, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'The Global Influenza Market' is expected to grow from $9.0 billion in 2024 to $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029. This report offers a well-rounded analysis of the global influenza market, covering both historical and current trends. It examines the disease burden, vaccine coverage, and market dynamics across the major regions of North America, Europe, and Asia-Pacific. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests). It also highlights leading products, clinical trials, new approvals, and emerging technologies. Additionally, the report profiles major companies and outlines their strategies, while providing growth forecasts and opportunities for each product segment in major regions. This report is particularly relevant today because public health systems and healthcare providers need to prepare for a potential rise in influenza cases. It helps forecast how many people could need to seek medical care, what quantity of drugs or vaccines will be needed, and which resources such as hospital beds or antivirals might be stretched. For pharmaceutical companies, the report is crucial for identifying areas with strong demand and adjusting their production or distribution strategies accordingly to ensure the timely and efficient delivery of flu vaccines and treatments. The factors driving the market's growth include: Faster Testing Technologies: New rapid tests and molecular tools help detect flu viruses quickly and accurately. This allows doctors to treat patients sooner and helps prevent the spread of the virus, boosting demand for diagnostics. Government Support: Governments are funding research and speeding up approvals for new flu treatments and tests. This support encourages innovation and helps bring new products to market faster. More Vaccine Awareness: People are more aware of the importance of flu shots, especially after recent global health events. Public campaigns and easier access to vaccines have led to higher vaccination rates. Request a sample copy of the global influenza market report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $8.4 billion Market size forecast $12.8 billion Growth rate CAGR of 7.2% for the forecast period of 2024-2029 Segments covered Vaccines, Therapeutics, Diagnostics, and Region Regions covered North America, Asia-Pacific, Europe, Rest of the World (includes South America, and the Middle East and Africa) Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, Australia, Market drivers • Development of rapid tests and molecular technologies. • Government support and funding for novel therapies and diagnosis. • Rising public awareness of the need for flu vaccines. Interesting facts: GSK Begins Early Flu Vaccine Distribution: Ahead of the 2024–2025 flu season, GSK plc has started shipping its trivalent influenza vaccines across the U.S. This rollout follows the FDA's approval of the lot release and licensing, ensuring timely availability at pharmacies and healthcare facilities. Sanofi's Dual Vaccine Candidates Fast-Tracked: In December 2024, the FDA granted Fast Track designation to two of Sanofi's combination vaccine candidates designed to protect individuals 50 and older from influenza and COVID-19. These candidates merge two already approved vaccines, each proven effective and well-tolerated in clinical trials. FluMist, the First Self-Administered Flu Vaccine Approved in the U.S.: In a groundbreaking move, the FDA approved FluMist in 2024 as the only self-administered influenza vaccine available in the U.S. Adults up to age 49 can now use this needle-free nasal spray on their own, while parents or caregivers can administer it to children 2 to 17. The approval was based on a comprehensive submission, including a usability study confirming that adults could safely administer the vaccine to themselves or others within the eligible age range. Emerging startups Ansun BioPharma Virolock Technologies Vaxart The report addresses the following questions: What is the projected size and growth rate of the market?–The global influenza market was valued at $8.4 billion in 2023 and is expected to reach $12.8 billion by the end of 2029. The market is expected to grow at a CAGR of 7.2% from 2024 to 2029. What factors are driving the growth of the market?– Factors that are driving the market's growth are the development of rapid tests and molecular technologies, government support and funding for novel therapies and diagnosis, and rising public awareness about flu vaccines. Which market segments are covered in the report?– The market size for influenza is categorized into three product segments: Vaccines, Therapeutics, and Diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. The diagnostics, market is divided into rapid tests and conventional lab tests. Which product segment will be dominant through 2029?– Vaccines will be the dominant market segment through 2029. Which region has the highest market share?–The North American market for influenza was valued at $4.2 billion in 2023 and is projected to reach $6.3 billion in 2029, at a CAGR of 7.3% during the forecast period. Market leaders include: ABBOTT ASTRAZENECA BECTON DICKINSON BIOCRYST PHARMACEUTICALS INC. CSL DAIICHI SANKYO CO. LTD. DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GSK PLC. HOLOGIC INC. QUIDELORTHO CORP. SANOFI SEKISUI DIAGNOSTICS THERMO FISHER SCIENTIFIC INC. VIATRIS INC. Related reports: Global Markets for Vaccine Technologies: This report provides an in-depth look at the human vaccine industry, focusing on key trends, market drivers and restraints, and the impact of new technologies and competition. It covers vaccine types, including pneumococcal, HPV, MMR, and influenza, but excludes animal vaccines. The study also examines R&D spending, product launches, and strategic moves like mergers, acquisitions and collaborations. It offers insights for stakeholders such as manufacturers, researchers, healthcare providers, and government agencies, with detailed regional analysis to support market expansion efforts. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo –
Malaysian Reserve
10 hours ago
- Malaysian Reserve
Feel Good Foods Delivers Craveable, Gluten-Free Satisfaction With New Crispy Chicken Bites
NEW YORK, July 15, 2025 /PRNewswire/ — The rumors are true: Feel Good Foods®, the #1 Natural Brand in Frozen Snacks & Appetizers, has launched the ultimate crave-worthy snack: gluten-free Crispy Chicken Bites! 'These Crispy Chicken Bites deliver delicious flavor in every bite. It's elevated comfort food – you'd never believe they're gluten-free!' says Vanessa Phillips, founder of Feel Good Foods. Tender, crispy, and with 16 grams of protein per serving, these Feel Good Foods Crispy Chicken Bites are made to satisfy and fuel. Each 10oz pack contains white meat chicken bites fried to perfection in a crispy tempura batter and served with sweet chili dipping sauce. Made with real, simple ingredients and certified gluten-free, consumers can feel good about indulging in these chicken bites. Cooking in just minutes in the air fryer or oven, Feel Good Foods Crispy Chicken Bites are designed to deliver a deliciously satisfying experience that requires minimal time and effort. This new addition to the Feel Good Foods portfolio is poised to appeal to a broad audience of crispy chicken lovers, gluten-free or not. Feel Good Foods Crispy Chicken Bites joins an all-star lineup of delicious consumer favorites, including new Mini Pizza Bagels, Mozzarella Sticks, and Pancake Balls. About Feel Good Foods:Feel Good Foods is a company specializing in simple, delicious, certified gluten-free frozen snacks, appetizers, and breakfast. Founded by Vanessa Phillips, who was diagnosed with celiac disease, the company aims to recreate beloved comfort foods without gluten, ensuring that everyone, including gluten-free consumers, can enjoy their favorite dishes. Learn More by visiting and following Feel Good Foods on social media:Instagram: @feelgoodfoods Facebook: Feel Good FoodsTikTok: @feelgf Contact: mediarelations@
